Corbus Pharmaceuticals Holdings Inc. Common Stock (CRBP)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I start with business quality. Corbus is a 36-employee clinical-stage biotech with no revenue in any filed period I was given. It is developing CRB-701 and CRB-913, but neither has approved sales. That means no durable competitive moat is demonstrated by earnings power; any moat would be speculative intellectual property or trial data. The computed Lynch category is none, because it has lost money in each of the last four years. Financial health is poor. In fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $35.0M, or $1.81 per diluted share. Fiscal Q1 2026 lost $23.0M, or $1.23. FY2025 net loss was $78.5M, worse than FY2024's $40.2M. The company burned $86.7M of free cash flow over trailing twelve months, a FairStock calculation, equating to a -93.8% FCF yield. FairStock's Piotroski score is 1/9 and Altman Z-score is -3.56, both flashing distress. The one balance-sheet positive is low debt: D/E of 0.04. But low debt is not solvency if cash burn persists; equity raises are likely. Valuation: at the 2026-10-13 close of $4.78, FairStock calculates P/B 0.87 and P/E -0.78. A negative P/E is not a bargain; it reflects losses. P/B below one may suggest asset support, but for a clinical-stage biotech book value can disappear through R&D burn. The 52-week range, $4.76-$20.56, shows the market has repriced risk sharply. Beta 2.64 means high volatility. This is not a Graham defensive investment; it is a speculative, binary clinical bet. Growth trajectory depends entirely on trial readouts and financing, not present earnings. I would demand a clearer cash runway and evidence of clinical validation before seeing a margin of safety.

In plain English: Corbus is a small clinical-stage drug developer working on cancer and obesity treatments. It has no product sales and loses money each year, so the business looks financially weak and depends on trial success or new funding. At the recent price, the stock looks speculative rather than clearly cheap or fair because there are no profits or revenue to anchor value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer